Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Faktory patogenity Staphylococcus Pettenkoferi u ran na nohou a osteitidy u diabetiků (PETTENK-OS)

22. září 2026 aktualizováno: Centre Hospitalier Universitaire de Nīmes

Hodnocení faktorů patogenity Staphylococcus Pettenkoferi u poranění nohou a osteitidy u diabetiků. Studie PETTENK-OS

Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.

At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.

Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.

A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.

Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.

Typ studie

Pozorovací

Zápis (Aktuální)

230

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Gard
      • Nîmes, Gard, Francie, 30029
        • Nîmes University Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dítě
  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.

Popis

Inclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Exclusion Criteria:

  • Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: OTHER

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Časové okno: Day 0 to 3 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms).

Day 0 to 3 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Časové okno: 3 - 6 months

Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances.

3 - 6 months
Resistome in the strain population according to sample origin:osteitis
Časové okno: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: non-diabetic wounds
Časové okno: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: diabetic wounds
Časové okno: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: blood cultures
Časové okno: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Resistome in the strain population according to sample origin: nasal carriage
Časové okno: 3 - 6 months

The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: osteitis
Časové okno: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: non-diabetic wounds
Časové okno: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: diabetic wounds
Časové okno: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: blood cultures
Časové okno: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Virulome in the strain population according to sample origin: nasal carriage
Časové okno: 3 - 6 months

The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: osteitis
Časové okno: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Časové okno: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: diabetic wounds
Časové okno: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: blood cultures
Časové okno: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Plasmids inthe strain population and according to sample origin: nasal carriage
Časové okno: 3 - 6 months

The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes.

3 - 6 months
Phenotypic resistance profiles in the population in a subsample of 85 strains
Časové okno: 6 - 14 months

The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Časové okno: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Časové okno: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Časové okno: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Časové okno: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Časové okno: 6 - 14 months

Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin.

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Časové okno: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Časové okno: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Časové okno: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Časové okno: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Časové okno: 6 - 14 months

Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Časové okno: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Časové okno: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Časové okno: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Časové okno: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Časové okno: 6 - 14 months

Bacterial growth curve by measuring absorbance on bacterial culture over time.

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Časové okno: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Časové okno: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Časové okno: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Časové okno: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Časové okno: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Časové okno: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Časové okno: 6 - 14 months

The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1)

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Časové okno: 6 - 14 months

The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7).

6 - 14 months
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Časové okno: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Časové okno: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Časové okno: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Časové okno: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Časové okno: Up to 48 hours

Survival curve at 48 hours

Up to 48 hours

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Spolupracovníci

Vyšetřovatelé

  • Vrchní vyšetřovatel: Chloé MAGNAN, Dr., Nîmes University Hospital, FRANCE

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. ledna 2024

Primární dokončení (Aktuální)

31. prosince 2025

Dokončení studie (Aktuální)

31. prosince 2025

Termíny zápisu do studia

První předloženo

9. listopadu 2024

První předloženo, které splnilo kritéria kontroly kvality

12. listopadu 2024

První zveřejněno (Aktuální)

14. listopadu 2024

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

22. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • NIMAO/2023-2/CM-01

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .